Clinical Data, Inc. and Roche Diagnostics have signed a co-marketing agreement in support of the installation by the Cogenics Division of Clinical Data, of a 454 Genome Sequencer FLX System in one of their European facilities.
Cogenics plans to offer the 454 GS FLX ‘Next Generation’ sequencing technology as a fee-for-service offering to clients worldwide, with applications ranging from whole genome sequencing to genome wide expression profiling, and will collaborate with Roche to co-market the service.
“The Genome Sequencer FLX represents the most advanced state-of-the-art, high throughput and cost-effective sequencing technology to support the expectations and needs of our customers’ research,” stated Robert Bondaryk, Ph.D., Senior Vice President and General Manager of Cogenics.
“With our proven track record of offering sequencing services in both research and regulated environments, this next generation platform will give us increased sales opportunities and accelerate revenue growth across the broad array of molecular biology services that Cogenics offers. We look forward to our collaboration with Roche to present a new generation of sequencing solutions to genomics researchers globally.”
"We are pleased to offer our customers access to the 454 GS FLX platform supported by our recognized experience and expertise in genomics and pharmacogenomics,” said Paul Tomlin, Cogenics Director of European Operations.
“As a partner of major genomic projects such as the sequencing of the Tomato Genome within the Solanacea Genome Network and several large re-sequencing projects for SNPs discovery and gene profiling studies, Cogenics has already established itself as a worldwide leader in this field. Now we intend to consolidate this position through the installation of cutting edge platforms like the 454 GS FLX together with the co-marketing agreement with Roche.”
“We are glad to welcome Clinical Data in the fast growing family of Genome Sequencer users. Clinical Data's Cogenics Division is a well-known company in the sequencing world, and we regard their decision as a recommendation to use our technology,” said Manfred Baier, Head of Roche Applied Science in Penzberg/Germany.